Unlock instant, AI-driven research and patent intelligence for your innovation.

TNFR-Fc fusion protein and usage thereof

A fusion protein, human immunoglobulin technology, applied in the field of new recombinant TNFR-Fc fusion protein, can solve the problems of low biological activity, low binding ability, short effective time and so on

Active Publication Date: 2014-05-07
GENOR BIOPHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a variety of marketed TNF molecular antagonist drugs including Enbrel, because these drugs have the possibility of inducing ADCC and CDC in vivo (Tracey D, et al., Pharmacol Ther.2008; 117(2): 244-79) , so these drugs have certain side effects
[0006] However, the currently found TNFα-binding preparations still have low binding capacity, low biological activity, and short effective action time in vivo. Therefore, it is necessary to further study improved drugs in this field to effectively improve drug efficacy.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • TNFR-Fc fusion protein and usage thereof
  • TNFR-Fc fusion protein and usage thereof
  • TNFR-Fc fusion protein and usage thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0095] Example 1. Obtaining of hTNFRII-Fc fusion gene expression plasmid

[0096] 1. Acquisition of hTNFRII-hIgG2 / Fc gene

[0097] hTNFRII-hIgG2 / Fc is a fusion protein, its gene sequence has 1389bp, and it encodes a protein of 463 amino acids. Among them, the N-terminal hTNFRII extracellular region soluble fragment (mature protein) gene (705bp / 235aa), the sequence is as SEQ ID NO: 1 (derived from Genebank NM001066); the C-terminal hIgG2-Fc gene (684bp / 228aa), the sequence is SEQ ID NO : 2 (derived from Genebank AK131045).

[0098] Design oligonucleotide fragments for synthetic genes (Table 1): the length of the fragments is generally about 70 bases, and there are about 15 bases complementary between two adjacent oligonucleotide fragments. Try to ensure that each oligonucleotide The annealing temperature of the complementary bases of the fragments is the same. The hTNFRII gene was assembled and synthesized by overlap extension PCR.

[0099] Table 1 The artificially synthesi...

Embodiment 2

[0130] Expression and purification of embodiment 2.hTNFRII-Fc fusion gene

[0131] 1. Transfection and screening of CHO cells

[0132] Cell line and culture conditions: FreeStyle CHO-S cells (Invitrogen), culture conditions are freestyle medium (Invitrogen), containing 10% dialyzed serum (Hyclone), cultured in 10% CO 2 , 37 ℃ thermostat. G418, MSX (Sigma).

[0133] Lipofectamine produced by Invitrogen was used for transfection TM 2000 liposome transfection kit, operate according to the instructions. As a control, CHO-S cells were transfected with pIRES empty vector. G418 (200 μM) and MSX (50 μg / ml) were used for combined pressurization screening, and the medium was replaced once every 3 days. After 20 days of pressurization, transfer to a 96-well plate for culture and screening by the limiting dilution method. After 1 week of culture, the culture supernatant was taken for ELISA Determination.

[0134] Mouse anti-human TNFR primary antibody (Sigma) was coated with ELISA ...

Embodiment 3

[0141] Embodiment 3. Physicochemical activity detection of hTNFRII-Fc fusion protein

[0142] 1. SDS-PAGE protein electrophoresis and Western blotting

[0143] Take 20 μl of purified protein for SDS-PAGE electrophoresis, the concentration of the electrophoresis separation gel is selected as 10%, the result is as follows Figure 4 . Please refer to the second edition of "Molecular Cloning" and the experimental technique of protein electrophoresis for the specific operation steps.

[0144] The samples were separated by SDS-PAGE electrophoresis and transferred to nitrocellulose membrane. The membrane was blocked with 5% milk solution containing 0.5% Tween and bound to antibodies, the primary antibody was mouse anti-human TNFR (Sigma), the secondary antibody was goat anti-mouse IgG (Calbiochem) labeled with horseradish peroxidase, PBS / 0.5% Tween washed 3 times, TMB color development, the results are as follows Figure 5 .

[0145] 2.L929 Cytotoxicity Neutralization Test

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention relates to a TNFR-Fc fusion protein and usage thereof. By adopting molecular biological technology, cell biological technology and immunological technology, the invention builds a fusion protein of soluble segment of human TNFa receptor and Fc segment of human IgG2. The fusion protein can be used for the prevention or treatment of diseases related to TNFa abnormal activation. The fusion protein has the advantages that the TNFa combination effect is extremely excellent, the stability is good, the half life is long and the side effect is low.

Description

technical field [0001] The invention belongs to the field of molecular biology, and relates to a new recombinant TNFR-Fc fusion protein and its application. Background technique [0002] Human tumor necrosis factor (hTNF-α) is mainly a cytokine produced by activated monocytes / macrophages, which is a cytokine with various biological effects. Early studies have found that TNF-α can induce tumor Cell necrosis or apoptosis, but later found that TNF-α is the main cytokine mediating inflammatory response, and also an important factor causing fever and septic shock, and plays an important role in heart failure, transplant rejection and autoimmune diseases. An appropriate amount of TNF-α can activate the immune system and enhance immunity, and plays a key role in the host's defense system against microbial invasion and tumor suppression. However, when excessive TNF-α is expressed, it can produce various pathological damages together with other inflammatory factors. Therefore, TNF-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/63C12N5/10A61K38/17A61P19/00A61P19/02A61P29/00A61P17/06A61P31/00A61P11/00A61P9/10A61P3/10A61P1/00
Inventor 张爱晖王威徐翠云
Owner GENOR BIOPHARMA